

Operations, Office of Minority Health, 5515 Security Lane, Suite 1000, Rockville, Maryland 20852, telephone number (301) 594-0769.

The Catalog of Federal Domestic Assistance number is 93.910.

Dated: January 13, 1997.

Clay E. Simpson, Jr.,
Deputy Assistant Secretary for Minority Health.

[FR Doc. 97-3017 Filed 2-6-97; 8:45 am]

BILLING CODE 4160-17-M

Meeting of Commission on Dietary Supplement Labels

AGENCY: Office of Disease Prevention and Health Promotion.

ACTION: Commission on Dietary Supplement Labels: Notice of meeting #8.

SUMMARY: The Department of Health and Human Services (HHS) is providing notice of the eighth meeting of the Commission on Dietary Supplement Labels.

DATES: The Commission intends to hold its meetings on March 4, 1997 from 1:00 p.m. to approximately 5:00 p.m., E.S.T., at the Omni Hotel, 101 West Fayette Street, Baltimore, Maryland 21201. The meeting is open to the public; seating is limited.

FOR FURTHER INFORMATION CONTACT: Kenneth D. Fisher, Ph.D., Executive Director, Commission on Dietary Supplement Labels, Office of Disease Prevention and Health Promotion, Room 738G, Hubert H. Humphrey Building, 200 Independence Ave., SW., Washington, DC 20201, (202) 690-7102.

SUPPLEMENTARY INFORMATION: Public Law 103-417, Section 12, authorized the establishment of a Commission on Dietary Supplement Labels whose seven members have been appointed by the President. The appointments to the Commission by the President and the establishment of the Commission by the Secretary of Health and Human Services reflect the commitment of the President and the Secretary to the development of a sound and consistent regulatory policy on labeling of dietary supplements.

The Commission is charged with conducting a study and providing recommendations for regulation of label claims and statements for dietary supplements, including the use of supplemental literature in connection with their sale and, in addition, procedures for evaluation of label claims. The Commission is expected to evaluate how best to provide truthful, scientifically valid, and non-misleading information to consumers in order that

they may make informed health care choices for themselves and their families. The Commission's study report may include recommendations on legislation, if appropriate and necessary.

The Commission meeting agenda will include approval of minutes of the previous meeting, determination of the appropriateness and possible date for release of the Commission's final draft report for public review, review of certain materials drafted for possible inclusion in the Commission's report, and discussion of the process for review of Commission's final draft report. In addition, the Commission has requested further comments from several organizations that previously provided testimony and statements concerning (1) regulatory management of herbal remedies, and (2) possible use of third parties for evaluation of dietary supplement label claims. Oral statements and the required written statements of invited parties are to be restricted to additional views, data, and comments on these two topics. If time permits after the statements of the invited organizations, the Chair may allow brief oral statements from other interested parties and persons concerning these two topics.

The meeting is open to the public; however seating is limited. If you will require a sign language interpreter, please call Sandra Saunders (202) 690-7102 by 4:30 p.m. E.S.T. on February 24, 1997.

Dated: January 30, 1997.

Linda D. Meyers,

*Acting Deputy Director, Office of Disease Prevention and Health Promotion,
Department of Health and Human Services.*

[FR Doc. 97-3018 Filed 2-6-97; 8:45 am]

BILLING CODE 4160-17-M

National Institutes of Health

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of General Medical Sciences Special Emphasis Panel meeting:

Name of Committee: Structural Biology of AIDS Related Proteins.

Date: February 18, 1997.

Time: 1:00 p.m.—until conclusion (approximately 3 hours).

Place: Natcher Building—Room 1 AS-13, 45 Center Drive, Bethesda, Maryland 20892-6200 (Telephone Conference).

Contact Person: Arthur L. Zachary, Ph.D., Scientific Review Administrator, NIGMS, Office of Scientific Review, 45 Center Drive,

Room 1AS-13, Bethesda, MD 20892-6200, 301-594-2886.

Purpose: To evaluate program project proposals.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

This meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The discussions of these proposals could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program Nos. 93.821, Biophysics and Physiological Sciences; 93.859, Pharmacological Sciences; 93.862, Genetics Research; 93.863, Cellular and Molecular Basis of Disease Research; 93.880, Minority Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS])

Dated: January 31, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97-3077 Filed 2-6-97; 8:45 am]

BILLING CODE 4140-01-M

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of General Medical Science meeting:

Committee Name: Minority Program Review Committee MARC, Minority Access to Research Careers Sub-Committee.

Date: February 20-21, 1997.

Time: 8:30 a.m.—adjournment.

Place: Natcher Conference Center, 45 Center Drive—Conference Room C1/C2, Bethesda, MD 20892-6200.

Contact Person: Richard I. Martinez, Ph.D., Scientific Review Administrator, NIGMS, 45 Center Drive, Room 1AS-19G, Bethesda, MD 20892-6200, 301-594-2849.

Purpose: To review institutional research training grant applications.

This meeting will be closed in accordance with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The discussions of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.821, Biophysics and Physiological Sciences; 93.859, Pharmacological Sciences; 93.862, Genetics Research; 93.863, Cellular and Molecular Basis of Disease Research; 93.880, Minority

Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS])

Dated: January 31, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97-3078 Filed 2-6-97; 8:45 am]

BILLING CODE 4140-01-M

Office of Extramural Research; Notice of Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Peer Review Oversight Group (PROG) on February 13-14, 1997, in the Rockledge II Centre, 6701 Rockledge Drive, Bethesda, Maryland 20817. The meeting will be held from 8:30 a.m. to 5 p.m. on February 13 and from 8:30 a.m. to 12 p.m. on February 14. The meeting is open to the public, with attendance limited to space available.

Topics for discussion include: NIH extramural electronic reinvention activities, the rating of grant applications, the integration of Neuroscience Reviews, and the review of multiple mechanisms within one review group.

The meeting agenda and roster of committee members are available on the World Wide Web via the NIH Home Page (<http://www.nih.gov.grants/>) or from Dr. Peggy McCardle, Executive Secretary, PROG, and Special Assistant to the Deputy Director for Extramural Research, OD, NIH, Building 1, Room 150, Bethesda, Maryland 20892, (301) 402-2246. Individuals who plan to attend the meeting and need special assistance, such as sign language interpretation or other special accommodations, should contact Dr. McCardle by February 7, 1997.

This meeting is being published less than 15 days prior to the meeting due to the urgent need to proceed with the meeting as scheduled in order to address these issues in a timely manner.

Dated: January 31, 1997.

Paula N. Hayes,

Acting Committee Management Officer, NIH.

[FR Doc. 97-3079 Filed 2-6-97; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Particle-Medicated Gene Delivery DNA Vaccines Against Dengue and Other Flavivirus Infections

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive world-wide license to practice the invention embodied in U.S. Patent No. 5,494,671, issued February 27, 1996 (U.S. Patent Application Serial No. 07/747,785, filed August 20, 1991), entitled "C-Terminally Truncated Dengue and Japanese Encephalitis Virus Envelope Proteins"; U.S. Patent Application Serial No. 08/250,802, filed May 27, 1994, entitled "Chimeric and/or Growth Restricted Flaviviruses" and related foreign patent applications to Auragen, Inc./Geniva, Inc. of Middleton, WI. The patent rights in these inventions have been assigned to the United States of America.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license may be limited to particle-mediated gene delivery DNA vaccines against Dengue and other flavivirus infections. This license will not include live virus, killed virus, or protein-based vaccines. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The patent describes the use of C-terminally truncated flavivirus envelope proteins in vaccines against flavivirus infections and also relates to recombinant viruses which encode the truncated protein. The patent applications are directed to recombinant, modified or viable chimeric flaviviruses for use in vaccine preparations against flavivirus infections. This technology further provides for a baculovirus having a recombinant dengue cDNA sequence which encodes dengue proteins and for a baculovirus having a recombinant Japanese B encephalitis virus cDNA sequence which encodes Japanese B encephalitis proteins. The applications also relate to vaccines produced from recombinant DNA.

ADDRESSES: Requests for a copy of the issued patent, patent application, inquiries, comments, and other materials relating to the contemplated license should be directed to: Gloria H. Richmond, Patent Advisor, Office of Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7057 ext 268; Facsimile: (301) 402-0220; E-mail: Gloria.Richmond@NIH.GOV. A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application. Applications for a non-exclusive or exclusive license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH on or before April 8, 1997 will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 28, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 97-3080 Filed 2-6-97; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Vaccines for Dengue and Other Flaviviruses

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a limited field of use exclusive world-wide license to practice the invention embodied in U.S. Patent No. 5,494,671, issued February 27, 1996 (U.S. Patent Application Serial No. 07/747,785, filed August 20, 1991), entitled "C-Terminally Truncated Dengue and Japanese Encephalitis Virus Envelope Proteins" to Hawaii Biotechnology Group, Inc. of Aiea, Hawaii. The patent rights in this invention have been assigned to the United States of America.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license may be limited to the field of subunit vaccines against Dengue and Japanese Encephalitis produced in animal cells. This license will not include live virus, killed virus or DNA-based vaccines or the use of vaccinia virus as a vector, or immunogen. This prospective exclusive license may be granted unless within 60 days from the